Health Affairs ISSN - 0278-2715 Volume 13 ISSUE 10 page 4589-4595
Journal link: https://health-affairs.com/
Abstract Link: https://health-affairs.com/13-10-4589-4595/
Submission 16 July 2025
Acceptance 28 Aug 2025
Publication 1 October 2025

Sickle Cell Disease: Pathophysiology and Management

[1]Dr. Kiran Jabbar, [2]Umer Tipu, [3]Isma Abbas, [4]Ahmed Haroon, [5]Zamin Abbas, [6]Danish Marwat

[1]Bahria medical and dental college, Karachi
[2]UHS, Lahore
[3]PIMS, Islamabad
[4]Service Hospital, Lahore
[5]Mayo Hospital, Lahore
[6]Sir Gangaram Hospital, Lahore

Abstract

Background

Sickle cell disease (SCD) is an inherited hemoglobinopathy due to a defectively structured hemoglobin S leading to red blood cell malformation, hemolysis, and recurrent vaso-occlusion crisis. Sickle cell disease is a global public health concern with the rampant spread of the disease in sub-Saharan Africa, the Middle East, and African descent population.

Objective

This report includes the overall pathophysiology of SCD and the practice of treatment, including curative, supportive, and pharmaceutical treatment.

Methods

Pathophysiology and treatment of SCD were searched for in published literature. Molecular mechanism, complication, and therapeutic intervention information was obtained.

Results

SCD results from polymerization of deoxygenated HbS into sickle morphology with resultant vascular occlusion and organ damage. Progress has occurred through increased hydroxyurea treatment, stem cell transplant, and gene modification techniques but with continued disparities in access.

Conclusion

Effective management of SCD is founded on an integrated, multidisciplinary disease-modifying therapy, care, and curative technology development approach. Access to therapy with correct diagnosis forms the foundation towards reducing the disease burden.

Key Words: Sickle cell disease, pathophysiology, hydroxyurea, vaso-occlusion, stem cell transplantation, gene therapy

Introduction

Sickle cell disease (SCD) is a worldwide genetic condition with significant influence on millions of people globally and imposes an extensive burden on health systems across the globe [1]. SCD arises as a result of a mutation in chromosome 11 of the β-globin gene that results in expression of a disease-causing hemoglobin variant, hemoglobin S (HbS) [2]. When HbS is deoxygenated, it will polymerize, and red

Health Affairs ISSN - 0278-2715 Volume 13 ISSUE 10 page 4589-4595
Journal link: https://health-affairs.com/
Abstract Link: https://health-affairs.com/13-10-4589-4595/
Submission 16 July 2025
Acceptance 28 Aug 2025
Publication 1 October 2025

Health Affairs ISSN - 0278-2715 Volume 13 ISSUE 10 page 4589-4595
Journal link: https://health-affairs.com/
Abstract Link: https://health-affairs.com/13-10-4589-4595/
Submission 16 July 2025
Acceptance 28 Aug 2025
Publication 1 October 2025

cells become crescent or twisted, forming sickles. Sickled red blood cells are rigid, brittle, and liable to hemolysis and to occlusion of vessels [3]. Presentation of SCD is thus heterogeneous, ranging from anemia and pain crisis to chronic organ damage and infect-ability. Worldwide, the burden of SCD is vast, with highest frequency of affectedness in sub-Saharan Africa, where 2% of all neonates can be so affected. Migration has raised awareness also in Europe, North America, and elsewhere [4].



Although it is a monogenic disorder, the disease is extremely heterogeneous in clinical severity, depending on genetic modifiers, environment, and access to care [5]. Pathophysiologic mechanisms of SCD are regulated by HbS polymerization under conditions of low oxygen tension, leading to cycles of recurrent sickling and unsickling. It leads to cell membrane deformation, reduction in red cell survival, and production of chronic hemolytic anemia [6]. In addition, adhesion of the sickle cell with vascular endothelium and pro-inflammatory mediators also enhance vaso-occlusion to lead to ischemic tissue injury. Cumulatively, chronic long-term insults are responsible for complications such as stroke, pulmonary hypertension, avascular necrosis, renal failure, and retinopathy [7]. Treatment for SCD has been optimized for decades. Supportive therapy such as blood transfusion and prophylaxis against infection remain effective. Hydroxyurea is the optimum disease-modifying agent that raises fetal hemoglobin and lowers complications. Hematopoietic stem cell transplantation is a potential cure, but not for all [8].

Health Affairs ISSN - 0278-2715 Volume 13 ISSUE 10 page 4589-4595
Journal link: https://health-affairs.com/
Abstract Link: https://health-affairs.com/13-10-4589-4595/
Submission 16 July 2025
Acceptance 28 Aug 2025
Publication 1 October 2025

Health Affairs ISSN - 0278-2715 Volume 13 ISSUE 10 page 4589-4595
Journal link: https://health-affairs.com/
Abstract Link: https://health-affairs.com/13-10-4589-4595/
Submission 16 July 2025
Acceptance 28 Aug 2025
Publication 1 October 2025



Gene editing tools such as CRISPR-Cas9 are relatively new and theoretically potent. There are, however, limitations to their manufacture into universally available drugs, particularly in regions where the biggest disease burdens occur in low-resource environments [9]. This paper would critically examine SCD pathophysiologic mechanisms and place in the spotlight prevalent practice of management. By incorporating upgrading of pharmacotherapy, supportive therapy, and curative therapy, the controversy attempts to place in the front line the necessity of a continuum of care to optimize patient outcome for this disabling chronic disease.

Methodology

The paper was written based on narrative review of peer-reviewed published literature on sickle cell disease. The databases used were PubMed, Scopus, and Google Scholar, and only published studies between the years 2000 and 2024 were taken into account. The keywords employed were "sickle cell disease," "pathophysiology," "management," "hydroxyurea," "stem cell transplantation," and "gene therapy." Peer-reviewed journals, clinical trials, and systematic reviews were given priority that included molecular mechanisms, complications, and treatment. Inclusion were clinical trials with either evidence of management at the clinical level or published etiology of SCD at the biological level. Exclusion were thin clinical data trials, generalizable case series, and published and performed outside the English-speaking world. Data extraction were for determination of most informative data on disease mechanisms, frequent complications, and treatment outcomes. Data were synthesized thematically to highlight the two-way emphasis of this review: understanding disease pathophysiology and definition of modern management. Methodology employed allows results reported to capture both basic science data and mainstream clinical consensus. The review is not a comprehensive report but rather a snapshot of concordance and direction of travel in the field.

Results

SCD is characterized by chronic hemolysis, vaso-occlusive crisis, and multi-organ complications. Hydroxyurea treatment for disease modification has reduced morbidity and stem cell transplant is curative. Gene-editing technologies on the horizon offer a new future in management.

Health Affairs ISSN - 0278-2715 Volume 13 ISSUE 10 page 4589-4595
Journal link: https://health-affairs.com/
Abstract Link: https://health-affairs.com/13-10-4589-4595/
Submission 16 July 2025
Acceptance 28 Aug 2025
Publication 1 October 2025

Health Affairs ISSN - 0278-2715 Volume 13 ISSUE 10 page 4589-4595
Journal link: https://health-affairs.com/
Abstract Link: https://health-affairs.com/13-10-4589-4595/
Submission 16 July 2025
Acceptance 28 Aug 2025
Publication 1 October 2025

Table 1: Common Complications of Sickle Cell Disease

Complication	Context/Description	Clinical Impact
Vaso-occlusive crisis	Repeated/unpleasant occurrence	Mild recurrent pain, hospitalization
Stroke	Reversible disability	Temporary neurological impairment, disability
Acute chest syndrome	Respiratory distress	Respiratory failure, high risk of death
Chronic anemia	Exhaustion/malaise	Fatigue, growth retardation
Renal impairment	Chronic kidney disease	Progression to chronic kidney disease
Splenic dysfunction	Increased susceptibility to infection	Increased risk of infection

Table 2: Therapeutic Options for Sickle Cell Disease

Treatment Modality	Mechanism of Action	Limitations
Hydroxyurea	Increases HbF, decreases sickling	Partial response in selected patients
Blood transfusion	Increases oxygen delivery capacity	Risk of iron overload, alloimmunization
Stem cell transplantation	Repairs defective hematopoietic system	Limited donors, costly
Gene therapy (investigational)	Corrects genetic defect or restores HbF	Still in trials, very costly

Discussion

Sickle cell disease is a global public health problem, especially among low- and middle-income countries where the resources are limited [10]. To establish an effective treatment strategy, understanding its pathophysiology is vitally important. Mechanistically, substitution of valine for glutamic acid at position six of the β-globin chain results in the formation of HbS [11]. Under decreasing oxygen tension, polymerization of the HbS causes sickling of the red cells. This generates a chain of events: hemolysis, endothelial impairment, consumption of nitric oxide, and inflammation all predisposing towards vaso-occlusion and tissue damage [12]. SCD morbidity, acute chest syndrome, stroke, and organ failure illustrate the systemic nature of the disease. Supportive treatment hydration, analgesia, and infection prophylaxis is standard in most institutions but supplemented by developments in disease-modifying treatment [13]. Hydroxyurea, more widely studied, prevents sickling by promoting fetal hemoglobin. Long-term benefit is decreased hospitalization, decreased pain crises, and enhanced survival. However, compliance, side effects, and response heterogeneity limit its use globally [14]. Therapeutic intervention is where the science stands today. Allogeneic hematopoietic stem cell transplantation is a wonderful treatment in children but limited by availability of donors, risk of graft-versus-host disease, and expense

Health Affairs ISSN - 0278-2715 Volume 13 ISSUE 10 page 4589-4595
Journal link: https://health-affairs.com/
Abstract Link: https://health-affairs.com/13-10-4589-4595/
Submission 16 July 2025
Acceptance 28 Aug 2025
Publication 1 October 2025

Health Affairs ISSN - 0278-2715 Volume 13 ISSUE 10 page 4589-4595
Journal link: https://health-affairs.com/
Abstract Link: https://health-affairs.com/13-10-4589-4595/
Submission 16 July 2025
Acceptance 28 Aug 2025
Publication 1 October 2025

[15]. Gene therapy is groundbreaking with encouraging outcomes being shown in clinical trials by either repairing the defective gene or de-repressing fetal hemoglobin [16]. Access is, however, the single patient de-motivator for the patient groups most affected by SCD. In addition, multi benefit care and neonatal screening interventions have been proven to prevent death, specifically infection. Patient education, prevention intervention, and psychosocial intervention must be brought under coordination for maximization of quality of life [17]. Interestingly, heterogeneity between high-income and low-resource settings emphasizes the most critical contribution of global health interventions. Systematically, pathophysiology of SCD explains its clinical polyphrenia, and survival and quality of life enhance evolutionary management [18]. Synergy-based strategy diplomatically seeking a middle ground between disease-modifying therapies, supportive care, and curative therapy is best. Demystifying access barriers, particularly where low resources exist, is the turning point for converting nascent gains into actualized global health benefit.

Conclusion

Sickle cell disease is a multigene, multifactorial disorder with the highest clinical significance. Improved therapy such as hydroxyurea, bone marrow transplant, and gene therapy revolutionized its treatment. Still, access issues, expense, and disparities in health remain. Any future action needs to be directed towards early diagnosis, equal access to new treatment, and continued efforts toward curative treatment. International multidisciplinary collaboration must continue to maximize outcomes and reduce the global burden of this debilitating disease.

Reference

1. Ahmed, S., & Ibrahim, U. (2024). The Roles of Acute and Chronic Marrow Dysfunctions in the Aetiology of Anaemia in Sickle Cell Disease: Pathogenesis and Management: Marrow dysfunction in SCD. *Orient Journal of Medicine*, *36*(3-4), 1-23.
2. Chaturvedi, P., & Shah, S. R. (2024). Assessing the clinical outcomes of voxelotor treatment in patients with sickle cell disease. *International Journal of Applied Sciences and Biotechnology*, *12*(1), 46-53.
3. Patel, Z. V., Prajjwal, P., Bethineedi, L. D., Patel, D. J., Khullar, K., Patel, H., ... & Amir, O. (2024). Newer modalities and updates in the management of sickle cell disease: a systematic review. *Journal of Blood Medicine*, 435-447.
4. Shah, S., Alberts, A. H., Ngo, T. B., & Lucke-Wold, B. (2024). Stroke in sickle cell patients, epidemiology, pathophysiology, systemic and surgical treatment options and prevention strategies. *Clinical and Translational Discovery*, *4*(4), e303.
5. Ugochi, C. M. J. (2025). Molecular Mechanisms and Therapeutic Advances in Sickle Cell Disease: Insights into Genetics, Pathophysiology, and Treatment Strategies. *Hematological Disorders in the Single-Cell Era*, *1*(1), 1-8.
6. Obeagu, E. I. (2024). Influence of Hemoglobin Variants on Vaso-Occlusive Phenomena in Sickle Cell Anemia: A Review. *International Journal of Medical Sciences and Pharma Research*, *10*(2), 54-59.
7. Chakravorty, S., & Greenough, A. (2025). Acute chest syndrome (ACS) in sickle cell disease (SCD): pathogenesis and pharmacotherapies in early clinical development. *Expert Opinion on Investigational Drugs*, (just-accepted).
8. Chatzidavid, S., Flevari, P., Tombrou, I., Anastasiadis, G., & Dimopoulou, M. (2024). Pulmonary hypertension in sickle cell disease: novel findings of gene polymorphisms related to

Health Affairs ISSN - 0278-2715 Volume 13 ISSUE 10 page 4589-4595
Journal link: https://health-affairs.com/
Abstract Link: https://health-affairs.com/13-10-4589-4595/
Submission 16 July 2025
Acceptance 28 Aug 2025
Publication 1 October 2025

pathophysiology. *International Journal of Molecular Sciences*, *25*(9), 4792.

9. Wang, Y., Garland, J. S., Fellah, S., Reis, M. N., Parsons, M. S., Guilliams, K. P., ... & Ford, A. L. (2024). Intracranial aneurysms in sickle cell disease are associated with hemodynamic stress and anemia. *Blood Advances*, *8*(18), 4823-4831.
10. Yassin, M., Minniti, C., Shah, N., Alkindi, S., Ata, F., Qari, M., ... & Capellini, M. D. (2025). Evidence and gaps in clinical outcomes of novel pharmacologic therapies for sickle cell disease: A systematic literature review highlighting insights from clinical trials and real-world studies. *Blood Reviews*, 101298.
11. Obeagu, E. I. (2025). Thrombosis risk in sickle cell disease with HIV co-infection: unraveling the complex interactions and clinical implications–a narrative review. *Annals of Medicine and Surgery*, *87*(8), 5070-5076.
12. Quang, T., Mostashari, G., Berning, E., Gopalan, B. P., Lizarralde-Iragorri, M. A., Lovins, D., ... & Tromberg, B. J. (2024). Non-invasive optical and laboratory hematologic biomarkers correlate in patients with sickle cell disease. *Biomedical Optics Express*, *15*(8), 4829-4841.
13. Tariq, H., Khurshid, F., Khan, M. H., Dilshad, A., Zain, A., Rasool, W., ... & Akbar, A. (2024). CRISPR/Cas9 in the treatment of sickle cell disease (SCD) and its comparison with traditional treatment approaches: a review. *Annals of Medicine and Surgery*, *86*(10), 5938-5946.
14. Belfer, I., Chen, W., Weber, W., Edwards, E., & Langevin, H. M. (2024). Unmet need: mechanistic and translational studies of sickle cell disease pain as a whole-person health challenge. *The Journal of Pain*, *25*(10), 104603.
15. Wang, Y., Yu, L., Deng, K., Packiarajan, M., Aguilar, A., An, S., ... & Engel, J. D. (2025). Novel, potent, and orally bioavailable LSD1 inhibitors induce fetal hemoglobin synthesis in a sickle cell disease mouse model. *Blood*, *146*(3), 356-368.
16. van Dijk, M. J., Ruiter, T. J., van der Veen, S., Rab, M. A., van Oirschot, B. A., Bos, J., ... & van Wijk, R. (2024). Metabolic blood profile and response to treatment with the pyruvate kinase activator mitapivat in patients with sickle cell disease. *HemaSphere*, *8*(6), e109.
17. Li, W., Pucka, A. Q., Debats, C., Reyes, B. A., Syed, F., O'Brien, A. R., ... & Wang, Y. (2024). Inflammation and autoimmunity are interrelated in patients with sickle cell disease at a steady-state condition: implications for vaso-occlusive crisis, pain, and sensory sensitivity. *Frontiers in Immunology*, *15*, 1288187.
18. D'Costa, M. P., Alva, M. S., Nejadghaderi, S. A., Al Bloushi, S. H., Al Shizawi, W. I. S., Muduli, N., ... & Al-Marzouqi, A. M. (2025). The Evaluation of Patient-Controlled Analgesia Compared to Standard Opioid Analgesic Therapy in Pain Management Among Patients With Sickle Cell Disease: A Systematic Review and Meta-Analysis Protocol. *Health Science Reports*, *8*(3), e70577.